Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier.

Etheridge T, Damodaran S, Schultz A, Richards KA, Gawdzik J, Yang B, Cryns V, Jarrard DF.

Asian J Urol. 2019 Jan;6(1):57-64. doi: 10.1016/j.ajur.2018.09.001. Epub 2018 Sep 15. Review.

2.

Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy.

Blute ML Jr, Damaschke N, Wagner J, Yang B, Gleave M, Fazli L, Shi F, Abel EJ, Downs TM, Huang W, Jarrard DF.

PLoS One. 2017 Feb 24;12(2):e0172048. doi: 10.1371/journal.pone.0172048. eCollection 2017.

3.

Stimulation of cellular senescent processes, including secretory phenotypes and anti-oxidant responses, after androgen deprivation therapy in human prostate cancer.

Kawata H, Kamiakito T, Nakaya T, Komatsubara M, Komatsu K, Morita T, Nagao Y, Tanaka A.

J Steroid Biochem Mol Biol. 2017 Jan;165(Pt B):219-227. doi: 10.1016/j.jsbmb.2016.06.007. Epub 2016 Jun 18.

PMID:
27329245
4.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
5.

Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.

Ghashghaei M, Niazi TM, Heravi M, Bekerat H, Trifiro M, Paliouras M, Muanza T.

Prostate. 2018 Jan;78(1):64-75. doi: 10.1002/pros.23445. Epub 2017 Nov 14. Erratum in: Prostate. 2018 Feb;78(3):239.

PMID:
29134684
6.

The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.

McNamara M, Sweeney C, Antonarakis ES, Armstrong AJ.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):306-318. doi: 10.1038/s41391-017-0014-9. Epub 2017 Dec 20. Review.

PMID:
29263421
7.
8.

Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.

Tucci M, Bertaglia V, Vignani F, Buttigliero C, Fiori C, Porpiglia F, Scagliotti GV, Di Maio M.

Eur Urol. 2016 Apr;69(4):563-573. doi: 10.1016/j.eururo.2015.09.013. Epub 2015 Sep 28. Review.

9.

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.

Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, Mason MD, Miladinovic B, James ND, Parmar MKB, Spears MR, Sweeney CJ, Sydes MR, Tran N, Tierney JF; STOPCaP Abiraterone Collaborators.

Eur J Cancer. 2017 Oct;84:88-101. doi: 10.1016/j.ejca.2017.07.003. Epub 2017 Aug 8. Review.

10.

Intermittent androgen deprivation therapy in advanced prostate cancer.

Alva A, Hussain M.

Curr Treat Options Oncol. 2014 Mar;15(1):127-36. doi: 10.1007/s11864-013-0272-2. Review.

PMID:
24395278
11.

Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo.

Ewald JA, Desotelle JA, Church DR, Yang B, Huang W, Laurila TA, Jarrard DF.

Prostate. 2013 Mar;73(4):337-45. doi: 10.1002/pros.22571. Epub 2012 Aug 21.

12.

Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations.

Castellan P, Marchioni M, Castellucci R, De Francesco P, Iantorno R, Schips L, Cindolo L.

Ther Clin Risk Manag. 2018 Dec 6;14:2341-2347. doi: 10.2147/TCRM.S159824. eCollection 2018. Review.

13.

Contemporary role of androgen deprivation therapy for prostate cancer.

Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schröder FH, Sternberg CN, Studer UE.

Eur Urol. 2012 Jan;61(1):11-25. doi: 10.1016/j.eururo.2011.08.026. Epub 2011 Aug 19. Review.

14.

Androgen deprivation therapy as backbone therapy in the management of prostate cancer.

Merseburger AS, Alcaraz A, von Klot CA.

Onco Targets Ther. 2016 Nov 29;9:7263-7274. eCollection 2016. Review.

15.

Androgen receptors in hormone-dependent and castration-resistant prostate cancer.

Shafi AA, Yen AE, Weigel NL.

Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13. Review.

PMID:
23859952
16.

Expression of senescence-associated beta-galactosidase in enlarged prostates from men with benign prostatic hyperplasia.

Choi J, Shendrik I, Peacocke M, Peehl D, Buttyan R, Ikeguchi EF, Katz AE, Benson MC.

Urology. 2000 Jul;56(1):160-6.

PMID:
10869659
17.

Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.

Botrel TE, Clark O, Lima Pompeo AC, Horta Bretas FF, Sadi MV, Ferreira U, Borges Dos Reis R.

PLoS One. 2016 Jun 16;11(6):e0157660. doi: 10.1371/journal.pone.0157660. eCollection 2016. Review.

18.

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.

Eur Urol. 2018 May;73(5):696-703. doi: 10.1016/j.eururo.2017.09.022. Epub 2017 Oct 23.

PMID:
29074061
19.

Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.

Harshman LC, Wang X, Nakabayashi M, Xie W, Valenca L, Werner L, Yu Y, Kantoff AM, Sweeney CJ, Mucci LA, Pomerantz M, Lee GS, Kantoff PW.

JAMA Oncol. 2015 Jul;1(4):495-504. doi: 10.1001/jamaoncol.2015.0829. Erratum in: JAMA Oncol. 2015 Jul;1(4):544.

20.

CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells.

Barakat DJ, Zhang J, Barberi T, Denmeade SR, Friedman AD, Paz-Priel I.

Oncogene. 2015 Nov 26;34(48):5912-22. doi: 10.1038/onc.2015.41. Epub 2015 Mar 16.

Supplemental Content

Support Center